Josh Schimmer
Stock Analyst at Evercore ISI Group
(3.66)
# 822
Out of 4,714 analysts
120
Total ratings
41.35%
Success rate
9.35%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRO Spero Therapeutics | Downgrades: In-Line | $5 | $1.10 | +354.55% | 4 | Dec 20, 2024 | |
| JANX Janux Therapeutics | Reiterates: Overweight | $200 | $53.92 | +270.92% | 6 | Dec 11, 2024 | |
| TRML Tourmaline Bio | Reiterates: Overweight | $25 | $21.43 | +16.66% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Reiterates: Overweight | n/a | $2.58 | - | 5 | Dec 11, 2024 | |
| RCKT Rocket Pharmaceuticals | Reiterates: Overweight | $65 | $12.56 | +417.52% | 4 | Nov 19, 2024 | |
| SEPN Septerna | Initiates: Overweight | $50 | $23.69 | +111.06% | 1 | Nov 19, 2024 | |
| SPRY ARS Pharmaceuticals | Reiterates: Overweight | $30 | $11.19 | +168.10% | 4 | Oct 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Downgrades: Neutral | n/a | $5.93 | - | 3 | Sep 23, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $2.06 | - | 2 | Sep 17, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $191 → $205 | $140.40 | +46.01% | 1 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $53.15 | +69.33% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $70 | $28.12 | +148.93% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.27 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $69.86 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.79 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.94 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.41 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $79.13 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $158.33 | - | 4 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $1.01 | +1,385.15% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $30.50 | +73.77% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $10.67 | +115.56% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $40.51 | +60.45% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $42.80 | +40.19% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $2.40 | +1,983.33% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $30.52 | +145.74% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.49 | +100.80% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $2.74 | +301.46% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $138.10 | -5.87% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $718.15 | +5.83% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $15.01 | -0.07% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $0.22 | +20,079.37% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $12.68 | +333.75% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.63 | +1,740.49% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $2.68 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $7.77 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $319.69 | -21.80% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3,500 → $4,600 | $9.18 | +50,008.93% | 4 | Jun 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $69.63 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $34.81 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $6.04 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $21.26 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $17.94 | +22.63% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.31 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $66.83 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $181.22 | -47.58% | 1 | Aug 17, 2017 |
Spero Therapeutics
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $1.10
Upside: +354.55%
Janux Therapeutics
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $53.92
Upside: +270.92%
Tourmaline Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $21.43
Upside: +16.66%
Zura Bio
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.58
Upside: -
Rocket Pharmaceuticals
Nov 19, 2024
Reiterates: Overweight
Price Target: $65
Current: $12.56
Upside: +417.52%
Septerna
Nov 19, 2024
Initiates: Overweight
Price Target: $50
Current: $23.69
Upside: +111.06%
ARS Pharmaceuticals
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $11.19
Upside: +168.10%
4D Molecular Therapeutics
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $5.93
Upside: -
Alector
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.06
Upside: -
Ascendis Pharma
Sep 17, 2024
Maintains: Outperform
Price Target: $191 → $205
Current: $140.40
Upside: +46.01%
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $53.15
Upside: +69.33%
Sep 16, 2024
Reiterates: Overweight
Price Target: $70
Current: $28.12
Upside: +148.93%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.27
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $69.86
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.79
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.94
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.41
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $79.13
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $158.33
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $1.01
Upside: +1,385.15%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $30.50
Upside: +73.77%
Aug 13, 2024
Initiates: Overweight
Price Target: $23
Current: $10.67
Upside: +115.56%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $40.51
Upside: +60.45%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $42.80
Upside: +40.19%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.40
Upside: +1,983.33%
May 6, 2024
Reiterates: Overweight
Price Target: $75
Current: $30.52
Upside: +145.74%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.49
Upside: +100.80%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $2.74
Upside: +301.46%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $138.10
Upside: -5.87%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $718.15
Upside: +5.83%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $15.01
Upside: -0.07%
Mar 25, 2021
Initiates: Outperform
Price Target: $45
Current: $0.22
Upside: +20,079.37%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $12.68
Upside: +333.75%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.63
Upside: +1,740.49%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $2.68
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $7.77
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $319.69
Upside: -21.80%
Jun 19, 2018
Upgrades: Outperform
Price Target: $3,500 → $4,600
Current: $9.18
Upside: +50,008.93%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $69.63
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $34.81
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $6.04
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $21.26
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $17.94
Upside: +22.63%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $9.31
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $66.83
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $181.22
Upside: -47.58%